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Bernard Royer,1,2 Fabrice Larosa,3 Faezeh Legrand,3 Pauline Gerritsen-van Schieveen,2
Michel Berard,2 Jean-Pierre Kantelip,2 Eric Deconinck1,3Mycophenolate mofetil (MMF) is an immunosuppressive drug used as a prophylactic agent to prevent acute
graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation (HSCT). After reduced-in-
tensity conditioning (RIC) regimen, administration of MMF orally 3 times a day (tid) seems to be more ben-
eficial than twice a day (bid). However, information regarding the pharmacokinetic (PK) parameters of
mycophenolic acid (MPA), the active metabolite of MMF, administered in this regimen are very limited.
We performed a prospective study in 15 patients for whom 3 sets of sampling were performed: at the be-
ginning of the treatment, after 1 week, and after 1 month. Two consecutive 8-hour sets of sampling were
performed at day 0 (D0) and D7. Plasma concentrations of MPA were quantified and areas under the curve
for 8 hours (AUC0-8), and maximal and through concentrations were calculated. The results show that
AUC0-8 increases between the beginning of treatment and the end of the first week, but remains stable there-
after. Moreover, a trend to lower AUC0-8 was observed for the patients who experienced GVHD$2 com-
pared to those patients who did not. The other PK parameters are not associated with pharmacodynamic
events. A limited sampling strategy with Bayesian estimators is currently under investigation to confirm these
data and the role of D7 AUC0-8 as a potential target of therapeutic drug monitoring (TDM).
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Mycophenolic acid (MPA), the active metabolite of
mycophenolate mofetil (MMF), is widely used as an im-
munosuppressive drug to prevent graft rejection in solid
organ transplantation [1,2]. Because of a better tolerance,
MMF has also been introduced in replacement of meth-
otrexate (MTX) in the prophylaxis of graft-versus-host
disease (GVHD) after hematopoietic stem cell trans-
plantation (HSCT) [3,4]. The administration of MMF
as prophylaxis ofGVHD is of particular interest after re-
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6/j.bbmt.2009.04.011regimens, by decreasing the intensity of myeloablation,
allow performingHSCT in patients who are not suitable
candidates for conventional conditioning because of age
or comorbidities, but induce higher rates of GVHD [5–
7]. In routine practice, because of a shorter half-life
(3 hours) after HSCT, the dose of MMF progressively
shifted from 15 mg/kg twice a day (bid) to 15 mg/kg 3
times a day (tid), resulting in a trend to a decrease of
the GHVD rate [5,8,9]. Moreover, this trend is sup-
ported by lower exposition to MPA (1 g bid) after
HSCT than after solid organ transplantation [5,10,11].
There are few data regarding the evolution of the phar-
macokinetics (PK) of MPA administered orally tid after
RIC HSCT [12,13]. In this study, we extensively de-
scribe the results of the PK parameters of MPA in such
situations and their potential impact on acute GVHD
(aGVHD) occurrence, in a view to standardize the best
time to perform therapeutic drug monitoring (TDM).PATIENTS AND METHODS
Patients
For this prospective study, patients were required
to be candidates for RIC HSCT as defined by the
Biol Blood Marrow Transplant 15:1134-1139, 2009 1135MPA Pharmacokinetics with tid RegimenEuropean Group for Blood and Marrow Transplanta-
tion (EBMT) [14], aged between 18 and 70 years, and
to provide written informed consent. Exclusion crite-
ria were progressive disease, hypersensitivity to
MMF, impossibility to perform the planned follow-
up, and patient’s refusal. Patient details (pathologies,
conditioning regimens, source of hematopoietic stem
cells, and cytomegalovirus [CMV] status) and MMF
doses are presented in Table 1. None of the patients
received antithymocyte globulin (ATG). Oral cyclo-
sporine (CsA; 5 mg/kg bid) was administered together
with oral MMF (15 mg/kg tid) for GVHD prophylaxis
to all patients, starting 3 days before stem cell infusion.
MMF was administered according to the patient’s
body weight (BW); 750 mg tid if BW was \70 kg,
1 g tid if BWwas $ 70 kg and adjusted to a trough
blood concentration not exceeding 3.5 mg/L. CsA
was targeted to maintain a 150-300 ng/mL blood level.
The cell infusion was performed 24-48 hours after the
end of conditioning regimen. aGVHD was graded us-
ing Glucksberg’s criteria [15]. Institutional ethical re-
view committee (Comite de Protection des Personnes
de Franche-Comte) approved the study.
Methods
Blood samples for PK were taken using EDTA-
containing tubes. Three sets of samples were planned:
at the beginning of the MMF treatment (day 0 [D1]), 1
week later (D7), and 1month after the beginning of the
treatment (M1). For the 2 first sets (D0 and D7), 2 8-
hour sets of samples covering 2 cycles of absorption
were taken. To deal with potential PK interference be-
cause of enterohepatic recirculation, 2 complete set of
samples were drawn at predose, 0.25, 0.5, 0.75, 1, 1.5,
2, 4, and 6 hours after the first administration of theTable 1. Main Characteristics of the Patients (pts) Included in the
Pts Gender Age Pathology
Conditioning
Regimen
Origin of
Stem Cells
Do
R
1 F 51 CML Flu, Mel BM
2 F 57 RAEB Flu, Mel PBMC
3 F 57 AML Flu, TBI PBMC
4 M 20 Hodgkin’s disease Flu, TBI PBMC
5 M 50 Primary idiopathic
myelofibrosis
Flu, Cy, TBI UCB
6 M 42 AML Flu, Mel PBMC
7 F 34 AML Flu, Cy, TBI UCB
8 F 60 AML Flu, Mel PBMC
9 M 50 CLL Flu, Cy, TBI PBMC
10 M 58 AML Flu, Mel BM
11 M 57 AML Flu, Mel PBMC
12 M 45 AML Flu, Cy, TBI UCB
13 M 51 AML Flu, Mel BM
14 F 47 Myeloma Flu, Mel PBMC
15 M 59 AML Flu, Bu PBMC
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic leuke
AML, acute myelogenous leukemia; Flu, fludarabine (25-50 mg/m2 for 3-5 days)
for 1 day); TBI, total body irradiation (2 Gy single dose); BM, bone marrow; PBM
presence of CMV reactivation; R2, absence of CMV reactivation; NA, not app
GVHD, graft-versus-host disease; ANC, absolute neutrophil count; Bu, busulfday (PK1), and at the same time points plus an addi-
tional sample 8 hours after the second dose of the
day (PK2). At M1, only PK1, extended to 8 hours,
was performed. After drawing, the samples were im-
mediately centrifuged and frozen until assay.
MPA determination in plasma was performed using
high-performance liquid chromatography (HPLC)
with ultraviolet (UV) detection according to Na-
Bangchang et al. [16]. Briefly, 250 mL of patient
plasma or standard was added to 10 mL of internal
standard (thiopental 400 mg/L), 500 mL of HCl
(0.02 N), and 4 mL of methylene chloride. After ex-
traction, the tubes were centrifuged and the organic
layer was evaporated with nitrogen. The samples
were reconstituted with HPLC mobile phase (58/
42 v/v mixture of NaH2PO4 buffer: 50 mM pH 2.7
and CH3CN). The samples were then assayed using
a Pursuit 5C18 150 4.6-mm column (Varian
SA, Les Ulis, France) and a photodiode array at
a wavelength of 254 nm. This method allows a lower
limit of quantification of 0.1 mg/L and a coefficient
of variation of 6.0% for interday variability with the
1 mg/L concentration. Linearity of the calibration
curve is observed between 0.1 and 20 mg/L. For
each set of samples, normalized (1000 mg) areas un-
der the concentration-time curves (AUC) were calcu-
lated by trapezoidal method. Trough and maximal
concentrations were graphically determined.
When indicated, nonparametricWilcoxon,Mann-
Whitney, or exact Fisher tests were performed to com-
pare data. Unless indicated, the results are expressed as
median with range.
Chimerism was assessed after 1 month and regu-
larly thereafter on blood nucleated cells, mononucle-
ated cells, granulocytes, and CD31 lymphocytes asStudy
nor
/U
MMF Dose
at D1 / D7 /
M1 (g)
CMV Status
(Donor/Recipient),
Reactivation
GVHD
Grade
Number of Days
to ANC >0.5G/L
R 1 / 1 / 1 2 / +, R+ 2 14
R 1 / 1 / — + / +, R+ 0 14
R 0.75 / 0.75 / 0.75 + / +, R2 1 21
R 1 / 0.75 / 0.75 + / +, R2 0 10
U 1 / 1 / 1.5 NA 3 21
U 1 / 1 / 1 2 /2 , R2 3 15
U 1 / 1 / 1 NA 2 16
R 1 / — / 0.75 + / +, R+ 0 13
U 1 / 1 / 1 + / -, R2 0 10
R 1 / 1 / 1 + / +, R2 0 21
U 1 / 0.5 / 0.5 + /2 , R2 1 20
U 1 / 1 / 1 2 /2 , R2 2 24
U 1 / 1 / 1 2 /2 , R2 0 14
R 1 / 1 / 1 2 / +, R2 2 13
U 1 / 1 / — 2 /2 , R2 0 12
mia; CMV, cytomegalovirus; RAEB, refractory anemia with excess blasts;
; Mel, melphalan (70 mg/m2 for 2 days); Cy, cyclophosphamide (70 mg/kg
C, peripheral blood mononuclear cells; UCB, umbilical cord blood; R+,
licable; donor R/U, related/unrelated; ANC, absolute neutrophil count;
an.
1136 Biol Blood Marrow Transplant 15:1134-1139, 2009B. Royer et al.previously described [17]. Complete engraftment was
defined by the presence of .95% CD31 donor lym-
phocytes in the blood.Figure 1. Mean concentration-time profiles of MPA for samples
obtained at D0 (A), D7 (B), andM1 (C) after the beginning of MMF treat-
ment. The results are the mean6 SD of 13 to15 patients.RESULTS
Median age at the first PK profile was 50.7 (20-60)
years. All aGVHD occurred before the M1 PK; no or
grade I aGVHD in 8 patients and grade $II aGVHD
observed in 7 patients (grade 2, n5 4 and grade III,
n5 2). Hematopoietic recovery was observed in all
patients with a median duration of 15 (10-24) days to
achieve a sustained absolute neutrophil count (ANC)
$0.5 G/L (Table 1). Complete donor engraftment
was documented in 11 patients at the end of the first
month and for all patients before the third month after
HSCT. Grade$3 nonhematologic toxicities were not
observed during the study duration.
Three sets of sampling could not be analyzed: 1 at
D7 because the patient was switched to intravenous
MMF, and 2 at M1 because 1 patient was switched to
tacrolimus and the other 1 presented with difficulties
to venous access. Seventy-one 8-hour cycles of MPA
PK were thus available for the analyses.
The mean concentration-time profiles for each
set of samples show a high interpatient variability
(Figure 1). The intraindividual variability was 20%
and the interindividual variability 44%. No entero-
hepatic recirculation, which could overlap the PK2
absorption was observed, and the AUC0-8 were not
statistically different between the PK1 and PK2 per-
formed the same day. Thus, to compare the AUC0-8
observed at each administration, the means of the 2
consecutive AUC0-8 of the same day were compared.
The high interpatient variability is also observed for
the dose-normalized AUCs obtained after each 8-
hour set (Figure 2). The median values of AUC0-8
were of 15.77 (6.99-31.62) mg/h/L and 16.69
(8.16-37.33) mg/h/L for the 2 respective PK of
D0, of 21.83 (8.96-49.99) and 20.70 (16.66-40.20)
for the 2 respective PK of D7, and of 24.08 (9.53-
52.08) mg/h/L for the PK performed at M1. The
mean AUC0-8 obtained at D7 (23.93 mg/h/L) and
AUC0-8 at D30 (26.20 mg/h/L) showed a statistically
significant increase (P\ .05) compared to the mean
AUC0-8 obtained at D0 (16.32 mg/h/L). No differ-
ence was observed regarding the AUC between D7
and D30. Mean concentrations were statistically dif-
ferent between PK1 and PK2 for D7 (0.80 versus
0.99 mg/L) [P\ .05] only, but not for PK2 between
D0, D7, and M1 [0.59 versus 0.99 versus 0.87 mg/
L]. Maximal concentrations were similar whatever
the tested sampling period.
All aGHVDwere observed before the M1 PK, and
we studied D0 and D7 PK parameters according to the
risk of aGVHD. A trend to a significant lower actualAUC0-8 for those patients who experienced aGVHD
$ii compared to those patients who did not could be
observed at D0 (P5 .099) and D7 (P5 .053) (Fig-
ure 3). At D7, patients with AUC0-8$ 22.5 mg/h/L
(5/14 patients) displayed no aGVHD $II compared
with patients with AUC0-8\22.5 mg/h/L (9/14 pa-
tients; 7 of 9 had GVHD $2); (P\ .05, exact Fisher
test). No similar difference is observed with the other
PK parameters and no PK parameters could be linked
with engraftment kinetics.
Figure 2. Normalized AUC0-8 obtained at D0 during the first (D0 PK1)
and the second administration (D0 PK2), at D7 during the first (D7 PK1)
and the second administration (D7 PK2), and at M1. The box represents
the 25th and 75th percentiles with the median as a solid line, and the
whiskers the 5th/95th percentiles.
Biol Blood Marrow Transplant 15:1134-1139, 2009 1137MPA Pharmacokinetics with tid RegimenDISCUSSION
This study presents the PK parameters ofMPA ad-
ministered tid as GHVD prophylaxis for RIC HSCT.
During the first week, the AUC0-8 increases, but
remains stable thereafter. This is consistent with a
3-hour half-life for MPA as described by Maris et al.
[8] during HSCT and the fact that the steady state is
reached at D7. Moreover, the increase of MPA expo-
sure after the beginning of the treatment is a known
phenomenon, already described during HSCT even
with i.v. administration of MMF [18]. Giaccone et al.
[5] also find that exposure of MPA is stable between
D7 and D21 with a tid oral administration. These re-
sults tend to show a stability of MPA exposure as
soon as 1 week after oral administration and
strengthen the interest of administering MMF 1
week before cell infusion that will then be performed
at steady state.Figure 3. Actual values of AUC0-8 obtained in patients with
aGHVD $2 (black dots) and patients with aGVHD\2 (open circles).The results are close to those already published re-
garding the AUC0-8, when MMF is administered in
similar conditions: mean values between 16.32 and
26.20 for our study versus mean values between 15.9
and 16.9 for Okamura et al. [19], between 20.99 and
21.14 for Nash et al. [3], between 24.7 to 25.0 for Giac-
cone et al. [5], or between 16.48 and 18.80 for Jacobson
et al. [12]. Previous data about MPA pharmacokinetics
show that MPA undergoes enterohepatic recirculation
that is described to happen around 6 hours after the
absorption of MMF. However, in a tid regimen, inter-
individual PK variability of MPAmay lead to a delayed
enterohepatic recirculation, then an overlap between
this phenomenon and the absorption of MPA because
of its following administration. In the present study,
we perform PK sampling after 2 administrations of
MMF because of a potential overlap ofMPA enterohe-
patic recirculation during the second absorption
phase. We do not observe such phenomenon probably
because MMF was combined with CsA, which is
known to inhibit enterohepatic recirculation in kidney
transplantation [20].
GVHD has a major impact on morbidity and mor-
tality associated to HSCT [6,21]. Grade $II aGVHD
is associated with an increased risk of nonrelapse mor-
tality (NRM) and a decreased progression-free survival
(PFS) [21]. We investigate a potential relationship be-
tween MPA exposures, expressed as actual AUC0-8,
and grade $II aGVHD to assess the best parameters
to perform TDM. Despite a low number of patients,
we find that patients with aGVHD $II have lower ex-
posure than those with aGVHD\II. Only few authors
have found that exposures to MPA can be associated
with the rate of GVHD: Jacobson et al. [22] observed
that a low AUC of freeMPA is associated with a higher
risk of aGVHD $II; Osunkwo et al. [23] showed that
patients with trough concentrations between 1.0 and
3.5 mg/mL before M1 had a significantly reduced risk
of grade$II aGVHD, and Okamura et al. [19] showed
that patients with higher MPA exposures (MMF tid
versus bid) had a trend to lower incidence of aGVHD
$2 [19]. These results have been obtained under
variable conditions in terms of administration of
ATG, use of RIC or standard conditioning regimens,
and variable CsA or tacrolimus protocols making com-
parisons difficult. Jacobson et al. [12] also stressed the
differences in the conditioning regimens (including
the administration of ATGs), their impact on the PK
parameters of MPA, and their relations with GVHD
occurrence. In the present study, the homogeneity of
the studied population, the absence of ATG adminis-
tration, the closely monitored dose of CsA, and the
systematic use of RIC might lead to a situation with
a sufficient risk of aGVHD to observe differences in
theMPA exposures even if some heterogeneity (nature
of conditioning regimens and source of stem cells) per-
sist in our data. The best association between MPA
1138 Biol Blood Marrow Transplant 15:1134-1139, 2009B. Royer et al.exposure and aGHVD was observed on D7, this sam-
pling time thus appeared to be optimal for PK assess-
ment as a potential predictive factor of aGVHD. We
explore 3 sets of sampling, all after oral administration
and spread over 1 month, with 2 repetitive PK per-
formed on the same day. These 2 repetitive PK allow
the extensive study of the putative enterohepatic recir-
culation, which was only partially explored by Jacob-
son et al. [12]. Thus, if the global PK parameters are
similar to previously published data, we provide here
additional information about the best sampling time
to perform TDM and an extensive study of the intra-
individual variability, which is critical to perform
TDM as suggested by Perez-Simon et al. [13]. Further
studies are, however, needed to confirm our prelimi-
nary results and that AUC0-8 obtained at D7 is
a good candidate to perform TDM for the prevention
of GHVD.We choose to analyze totalMPA. Indeed, if
interesting results were observed by Jacobson et al.
[12] regarding the relationship between free MPA
and GVHD occurrence, the routine practice is to per-
form TDMwith total MPA; we thus assess parameters
that can be easily be used by most centers.
To conclude, this study suggests that performing
TDMwith AUC on D7 might be relevant for the clin-
ical follow-up of these patients. Two recent studies
showed the interest of TDM, especially in decreasing
the interpatient variability [19,24]. Moreover, Oka-
mura et al. [19] confirmed that MMF tid seems more
effective than bid regarding GVHD prophylaxis. The
need of TDM was also strengthened by the results of
the study of Jacobson et al. [12], in which the authors
observed that, at a fixed dose, the patients uncommonly
reached the wished AUC target for total MPA (13%-
27% for concentration at steady state). However, this
strategy needed 6 samples to perform theAUCcalcula-
tion. We are currently developing a limited sampling
strategy using a Bayesian estimator as those previously
published [25-28]. Such strategy performed at D7 may
be used to perform larger prospective studies to con-
firm present data.ACKNOWLEDGMENTS
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